bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report released on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald restated a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Wells Fargo & Company reduced their price target on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Wednesday, September 25th. Robert W. Baird reduced their price target on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, August 15th. Bank of America downgraded bluebird bio from a “buy” rating to a “neutral” rating and reduced their price target for the company from $3.00 to $0.50 in a report on Friday, November 15th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of bluebird bio in a research report on Friday, November 15th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $3.03.

bluebird bio Stock Up 7.2 %

BLUE opened at $0.41 on Tuesday. bluebird bio has a 12 month low of $0.29 and a 12 month high of $5.53. The company has a market cap of $78.75 million, a P/E ratio of -0.22 and a beta of 0.76. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The business’s 50-day moving average price is $0.45 and its 200-day moving average price is $0.74.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 322.46%. The business had revenue of $18.57 million for the quarter. On average, equities analysts expect that bluebird bio will post -1.35 EPS for the current year.

Institutional Trading of bluebird bio

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of bluebird bio by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after purchasing an additional 1,723,081 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of bluebird bio by 315.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after purchasing an additional 1,013,144 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 355,562 shares in the last quarter. FMR LLC boosted its position in shares of bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after purchasing an additional 186,903 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares in the last quarter. 87.43% of the stock is owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.